“Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression
Top Cited Papers
Open Access
- 20 July 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 207, 107322
Abstract
No abstract availableKeywords
This publication has 246 references indexed in Scilit:
- Interplay of Metabolome and Gut Microbiome in Individuals With Major Depressive Disorder vs Control IndividualsJAMA Psychiatry, 2023
- Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide StudyJAMA Psychiatry, 2023
- Inflammation, Lifestyle Factors, and the Microbiome‐Gut‐Brain Axis: Relevance to Depression and Antidepressant ActionClinical Pharmacology & Therapeutics, 2022
- Effect of Aspirin vs Placebo on the Prevention of Depression in Older PeopleJAMA Psychiatry, 2020
- Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II DepressionJAMA Psychiatry, 2019
- Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive EpisodesJAMA Psychiatry, 2015
- Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse EffectsJAMA Psychiatry, 2014
- Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 IndividualsJAMA Psychiatry, 2013
- A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant DepressionJAMA Psychiatry, 2013
- Major Depressive Disorder and Hypothalamic-Pituitary-Adrenal Axis ActivityArchives of General Psychiatry, 2009